Clinical relevance of discoveries in psychopharmacogenetics

Advances in Psychiatric Treatment

Volumn 10, Issue 6, 2004, Pages 455-465

  Tsapakis, Evangelia M ^a,d   Basu, Amlam ^b   Aitchison, Katherine J ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^d MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARRIER PROTEIN; CITALOPRAM; CLOZAPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DOPAMINE RECEPTOR; DRUG METABOLIZING ENZYME; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; INOSITOL POLYPHOSPHATE; LITHIUM; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PHOSPHOLIPASE C; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; YOHIMBINE;

AGRANULOCYTOSIS; AKATHISIA; ALZHEIMER DISEASE; ARTICLE; ATTENTION DEFICIT DISORDER; BODY WEIGHT DISORDER; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESEARCH; DRUG RESPONSE; DRUG SENSITIVITY; DRUG USE; EXTRAPYRAMIDAL SYMPTOM; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HYPERPROLACTINEMIA; MEDICAL ETHICS; METHODOLOGY; ORTHOSTATIC HYPOTENSION; PHARMACODYNAMICS; PHARMACOGENOMICS; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; TARDIVE DYSKINESIA; TREATMENT PLANNING; WEIGHT GAIN;

EID: 8644276269     PISSN: 13555146     EISSN: None     Source Type: Journal    
DOI: 10.1192/apt.10.6.455     Document Type: Article

References (55)

1. Abbott, A. (2003) With your genes? Take one of these, three times a day. Nature, 425, 760-762.
2. Aitchison, K. J. & Gill, M. (2002) Pharmacogenetics in the postgenomic era. In Behavioural Genetics in the Postgenomic Era (eds R. Plomin & J. C. DeFries), pp. 335-361. Washington, DC: American Psychological Association.
3. Aitchison, K. J., Jann, M. W., Zhao, J. H., et al (2000a) Clozapine pharmacokinetics and pharmacodynamics studied with CYP1A2-null mice. Journal of Psychopharmacology, 14, 353-359.
4. Aitchison, K. J., Jordan, B. D. & Sharma, T. (2000b) The relevance of ethnic influences on pharmacogenetics to the treatment of psychosis. Drug Metabolism and Drug Interactions, 16, 15-38.
5. Aitchison, K. J., Tandon, K., Ashworth, A., et al (2002) Pharmacogenetic studies of tricyclic antidepressant response and an association study of a noradrenaline transporter variant in depression. European Journal of Neuropsychopharmacology, 12 (suppl.), S92-S93.
6. Amouyel, P. (2002) Pharmacogenomics and pharmacogenetics of neurodegenerative diseases: towards new targets. Pharmacogenomics, 3, 1-3.
7. Arranz, M. J., Munro, J., Sham, P., et al (1998) Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophrenia Research, 32, 93-99.
8. Arranz, M. J., Munro, J., Birkett, J., et al (2000) Pharmacogenetic prediction of clozapine response. Lancet, 355 1615-1616.
9. Basile, V. S., Ozdemir, V., Masellis, M., et al (2000) A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Molecular Psychiatry, 5, 410-417.
10. Basile, V. S., Masellis, M., McIntyre, R. S., et al (2001) Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. Journal of Clinical Psychiatry, 62 (suppl. 23), 45-66.
11. Basile, V. S., Masellis, M., Potkin, S. G., et al (2002) Pharmacogenomics in schizophrenia: the quest for individualized therapy. Human Molecular Genetics, 11, 2517-2530.
12. -3591G polymorphisms and response to clozapine. Schizophrenia Research, 67 (suppl.), 52.
13. Basu, A., Tsapakis, E. M. & Aitchison, K. J. (2004b) Pharmacogenetics and psychiatry. Current Psychiatry Reports, 6 134-142.
14. Birkett, J. T., Arranz, M. J., Munro, J., et al (2000) Association analysis of the 5-HT5A gene in depression, psychosis and antipsychotic response. Neuroreport, 11, 2017-2020.
15. Brøsen, K. (1996) Drug-metabolising enzymes and therapeutic drug monitoring in psychiatry. Therapeutic Drug Monitoring, 18 393-396.
16. Buchanan, A., Califano, A., Kahn, J., et al (2002) Pharmacogenetics: ethical issues and policy options. Kennedy Institute of Ethics Journal, 12, 1-15.
17. Cacabelos, R. (2003) The application of functional genomics to Alzheimer's disease. Pharmacogenomics, 4, 597-621.
18. Clark, D., Arranz, M. J., Arrondo, J., et al (2002) Pharmacogenetic prediction of olanzapine response (abstract). American Journal of Medical Genetics, 114, P108.
19. Collier, D. A. (2003) Pharmacogenetics in psychosis. Drug News and Perspectives, 16, 159-165.
20. Dettling, M., Cascorbi, I., Roots, I., et al (2001) Genetic determinants of clozapine-induced agranulocytosis. Recent results of HLA subtyping in a non-Jewish Caucasian sample. Archives of General Psychiatry, 58, 93-94.
21. Ikeda, A & Kato, T. (2003) Biological predictors of lithium response in bipolar disorder. Psychiatry and Clinical Neurosciences 57, 243-250.
22. Ioannidis, J. P., Ntzani, E. E., Trikalinos, T. A., et al (2001) Replication validity of genetic association studies. Nature Genetics, 29, 306-309.
23. Jacobsen, F. M. (1992) Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. Journal of Clinical Psychiatry, 53, 119-122.
24. Johansson, I., Lundqvist, E., Bertilsson, L., et al (1993) Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause for ultrarapid metabolism of debrisoquine. Proceedings of the National Academy of Sciences of the United States of America, 90, 11825-11829.
25. Joober, R., Benkelfat, C., Brisebois, K., et al (1999) T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variability. Journal of Psychiatry and Neurosciences, 24, 141-146.
26. Kirchheiner, J., Brøsen, K., Dahl, M. L., et al (2001) CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatrica Scandinavica, 104, 173-192.
27. Lane, H. Y., Chang, Y. C., Chiu, C. C., et al (2002) Association of risperidone treatment response with a polymorphism in the 5-HT2A receptor gene. American Journal of Psychiatry, 159, 1593-1595.
28. Lerer, B., Segman, R. H., Fangerau, H., et al (2002) Pharmacogenetics of tardive dyskinesia. Combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology, 27, 105-119.
29. Liljedahl, U., Karlsson, J., Melhus, H., et al (2003) A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response. Pharmacogenetics, 13, 7-17.
30. Meged, S., Stein, D., Sitrota, P., et al (1999) Human leukocyte antigen typing, response to neuroleptics, and clozapine-induced agranulocytosis in Jewish Israeli schizophrenic patients. International Clinical Psychopharmacology, 14, 305-312.
31. Meisel, C., Gerloff, T., Kirchheiner, J., et al (2003) Implications of pharmacogenetics for individualising drug treatment and for study design. Journal of Molecular Medicine, 81, 154-167.
32. Meltzer, H. Y. (1995) The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics. Journal of Clinical Psychopharmacology, 15 (suppl. 1), 2S-3S.
33. Mihara, K., Kondo, T., Suzuki, A., et al (2000) Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Tag1A polymorphism of DRD2 gene. Psychopharmacology (Berlin), 149, 246-250.
34. Minov, C., Baghai, T. C., Schule, C., et al (2001) Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression. Neuroscience Letters, 303, 119-122.
35. Owens, M. J. & Nemeroff, C. B. (1994) Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clinical Chemistry, 40, 288-295.
36. Pritchard, J. K. & Rosenberg, N. A. (1999) Use of unlinked genetic markers to detect population stratification in association studies. American Journal of Human Genetics, 65, 220-228.
37. Reynolds, G. P., Zhang, Z. J. & Zhang, X. B. (2002) Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet, 359, 2086-2087.
38. Rohde, L. A., Roman, T. & Hutz, M. H. (2003) Attention-deficit/hyperactivity disorder: current aspects on pharmacogenetics. Pharmacogenomics Journal, 3, 11-13.
39. Sachse, C., Brockmoller, J., Bauer, S., et al (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. American Journal of Human Genetics, 60, 284-295.
40. Scordo, M. G. & Spina, E. (2002) Cytochrome P450 polymorphisms and response to antipsychotic therapy. Pharmacogenomics 3, 201-218.
41. Segman, R. H., Goltser, T., Heresco-Levy, U., et al (2003) Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia. Pharmacogenomics Journal, 3, 277-283.
42. Serretti, A., Zanardi, R., Cusin, C., et al (2001a Tryptophan hydroxylase gene associated with paroxetine anti-depressant activity. European Neuropsychopharmacology, 11 375-380.
43. Serretti, A., Zanardi, R., Rossini, D., et al (2001b Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Molecular Psychiatry, 6 586-592.
44. Serretti, A., Zanardi, R., Cusin, C., et al (2001c No association between dopamine D(2) and D(4) receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors. Psychiatry Research, 104, 195-203.
45. Serretti, A., Lilli, R. & Smeraldi, E. (2002) Pharmacogenetics in affective disorders. European Journal of Pharmacology, 438, 117-128.
46. Shaikh, S. & Kerwin, R. W. (2002) Receptor pharmacogenetics: relevance to CNS syndromes. British Journal of Clinical Pharmacology 54, 344-348.
47. Shannon, J. R., Flattem, N. L., Jordan, J., et al (2000) Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. New England Journal of Medicine 342, 541-549.
48. Staddon, S., Arranz, M. J., Mancama, D., et al (2002) Clinical applications of pharmacogenetics in psychiatry. Psychopharmacology (Berlin), 162, 18-23.
49. Tsapakis, E. M., Checkley, S., Kerwin, R. W., et al (2003) Association between the serotonin transporter linked polymorphic region gene (5-HTTLPR) and response to tricyclic antidepressants (TCAs). European Neuropsychopharmacology, 13 (suppl. 4), S250.
50. Urwin, R. E., Bennetts, B., Wilcken, B., et al (2002) Anorexia nervosa (restrictive subtype) is associated with a polymorphism in the novel norepinephrine transporter gene promoter polymorphic region. Molecular Psychiatry, 7, 652-657.
51. Valevski, A., Klein, T., Gazit, E., et al (1998) HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients. European Journal of Immunogenetics, 25 11-13.
52. Washizuka, S., Ikeda, A., Kato, N., et al (2003) Possible relationship between mitochondrial DNA polymorphisms and lithium response in bipolar disorder. International Journal of Neuropsychopharmacology, 6, 421-424.
53. Yu, Y. W., Tsai, S. J., Lin, C. H., et al (1999) Serotonin-6 receptor variant (C267T) and clinical response to clozapine. NeuroReport, 10, 1231-1233.
54. Zhang, Z. J., Zhang, X. B., Hou, G., et al (2003) Interaction between polymorphisms of the dopamine D3 receptor and manganese superoxide dismutase genes in susceptibility to tardive dyskinesia. Psychiatric Genetics, 13, 187-192.
55. Zill, P., Baghai, T. C., Zwanzger, P., et al (2000) Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment. NeuroReport, 11, 1893-1897.